2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

• Published in: Journal of the American College of Cardiology Vol. 83; no. 23; p. 2324
• Main Authors: Ommen, Steve R, Ho, Carolyn Y, Asif, Irfan M, Balaji, Seshadri, Burke, Michael A, Day, Sharlene M, Dearani, Joseph A, Epps, Kelly C, Evanovich, Lauren, Ferrari, Victor A, Joglar, José A, Khan, Sadiya S, Kim, Jeffrey J, Kittleson, Michelle M, Krittanawong, Chayakrit, Martinez, Matthew W, Mital, Seema, Naidu, Srihari S, Saberi, Sara, Semsarian, Christopher, Times, Sabrina, Waldman, Cynthia Burstein
• Format: Journal Article
• Language: English
• Published: United States 11.06.2024
• Subjects: ACC/AHA Clinical Practice Guidelines; occupation; risk stratification; echocardiography; exercise; systolic dysfunction; sudden cardiac death; left ventricular outflow tract obstruction; septal alcohol ablation; sarcomeric genes; cardiovascular magnetic resonance imaging; atrial fibrillation; genetics; shared decision-making; family screening; sports; athlete; rhythm monitoring; pregnancy; septal reduction therapy; cardiac myosin inhibitors; physical activity; exercise stress testing; implantable cardioverter defibrillator; surgical myectomy; ventricular arrhythmias; diastolic dysfunction; hypertrophic cardiomyopathy
• ISSN: 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2024.02.014

The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.